TICKERNERD
Menu
SIHealthcare · Medical Devices

SI Stock Forecast: Shoulder Innovations, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$19
−3.04% on the day

The 4 Wall Street analysts covering Shoulder Innovations, Inc. hold a median 12-month price target of $26 — +40.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$382.2M
Ticker Nerd rank
27 / 100
Median analyst target
$26
Analysts covering
4
Revenue$17.2M+56.0% y/y
Operating income−$10.0M
Net income−$10.2M
Free cash flow−$9.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.1%
1M
−5.6%
YTD
+29.6%
1Y
+23.5%
From 52W high
−23.6%
From 52W low
+68.3%
$11
$24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Shoulder Innovations, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
64
Size
57
Issuance
56
Growth
50
Revisions
43
Volatility
29
Quality
28
Value
24
Accruals
18

Momentum (64): The shares have been drifting up relative to others.

Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26SIHigh $28Median $26Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $25Median $26High $28

The green dot is the last close — the median target sits +40.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
10 Aug 2026UBSMaintainsBuy$27 → $28
7 Aug 2026BTIGMaintainsBuy$24 → $26
7 Aug 2026Piper SandlerReiteratesOverweight$19 → $25
28 July 2026UBSInitiatesBuy$27
28 July 2026UBSInitiatesBuy—
8 May 2026Piper SandlerReiteratesOverweight$18 → $19
8 May 2026Piper SandlerReiteratesOverweight—
11 Mar 2026BTIGMaintainsBuy—
2 Dec 2025Morgan StanleyMaintainsOverweight—
12 Nov 2025Piper SandlerReiteratesOverweight—
9 Sept 2025BTIGReiteratesBuy—
26 Aug 2025Morgan StanleyInitiatesOverweight—
25 Aug 2025Goldman SachsInitiatesBuy—
25 Aug 2025JefferiesInitiatesBuy—
25 Aug 2025Piper SandlerInitiatesOverweight—
6 Mar 2023WedbushDowngradeUnderperform$4.00
2 Mar 2023Canaccord GenuityDowngradeHold$25 → $9.00
2 Mar 2023JP MorganDowngradeUnderweight—
1 Mar 2023Keefe, Bruyette & WoodsDowngradeMarket Perform$25 → $16
9 Jan 2023Goldman SachsMaintainsNeutral$35 → $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Shoulder Innovations, Inc. returned +23.5% against +17.5% for the S&P 500, dividends included.

SI vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26SIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Shoulder Innovations, Inc. (SI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.0×

Cheaper than 89% of US stocks

Price / sales
8.1×

Cheaper than 16% of US stocks

Price / book
3.1×

Cheaper than 32% of US stocks

EV / EBITDA
−16.0×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
2.8%

Higher than 34% of US stocks

Earnings growth (YoY)
56.0%

Higher than 76% of US stocks

Gross margin
78.3%

Higher than 90% of US stocks

Operating margin
−85.1%

Higher than 14% of US stocks

Net margin
76.5%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−28.7%

Higher than 27% of US stocks

Return on assets
−23.8%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Shoulder Innovations, Inc. (SI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Shoulder Innovations, Inc. has a market value of $382.2M and an enterprise value of $370.3M.

  • Revenue in the twelve months to 30 June 2026: $60.1M. The latest quarter grew 2.8% year on year.

  • Net income over the same four quarters: −$35.0M, a −58.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.92.

  • Free cash flow in the twelve months to 30 June 2026: −$47.1M.

  • Shares outstanding: 20.8M.

  • Trailing P/E: −4.0×; forward P/E: −11.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Shoulder Innovations, Inc. employs 56 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SIShoulder Innovations, Inc.$382.2M
27
MASS908 Devices, Inc.$390.6M
83
PACBPacific Biosciences of California, Inc.$392.6M
44
CLPTClearpoint Neuro, Inc.$408.1M
20
OFIXOrthofix Medical, Inc.$353.6M
80
SGHTSight Sciences, Inc.$439.6M
90
VMDViemed Healthcare, Inc.$334.2M
93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Shoulder Innovations, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SI news & analysis

Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch

PRNewsWire · 10 Sept 2026positive

Shoulder Innovations received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity, and has initiated full commercial launch. This marks the second product introduction on the company's new line of technologies for metal-sensitive patients.

Why it matters — A SI watcher would care because this clearance expands the company's product portfolio and launch activity in a dedicated segment for metal-sensitive patients.

Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures

PRNewsWire · 9 Sept 2026positive

Shoulder Innovations announced an exclusive collaboration with ALM Ortho, a leader in additive manufacturing of titanium orthopedic implants, to introduce a bespoke implant for severe shoulder deformity and complex revision cases where no adequate solution currently exists.

Why it matters — The partnership expands SI's product pipeline into complex revision shoulder reconstruction, an underserved area that could broaden its market reach.

Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience

PRNewsWire · 8 Sept 2026positive

Shoulder Innovations, Inc. announced it has entered into a settlement agreement with Catalyst OrthoScience Inc. to resolve all outstanding patent litigation between the two companies. The settlement was announced on September 8, 2026.

Why it matters — Resolving the patent litigation removes a legal uncertainty facing Shoulder Innovations, which could clarify its position in the shoulder surgical care market.

Shoulder Innovations to Participate in the Morgan Stanley 24th Annual Healthcare Conference

PRNewsWire · 1 Sept 2026neutral

Shoulder Innovations, Inc. announced that members of its management team will participate in a fireside chat at the Morgan Stanley 24th Annual Healthcare Conference. The company made the announcement on September 1, 2026.

Why it matters — SI watchers would care because the management's participation at a major industry conference gives investors an opportunity to hear the company discuss its business and strategic direction.

Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer

PRNewsWire · 10 Aug 2026positive

Shoulder Innovations announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6, 2026. Osborne will lead commercial operations for the company, which focuses exclusively on shoulder surgical care.

Why it matters — A leadership change at the commercial helm can influence how Shoulder Innovations executes its sales and market-expansion strategy going forward.

FAQ

Frequently asked questions about SI stock

What is the SI stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Shoulder Innovations, Inc. have a median 12-month price target of $26, with estimates ranging from $25 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SI stock a buy right now?

Of the 4 analysts covering Shoulder Innovations, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Shoulder Innovations, Inc. 27 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SI?

As at 12 Sept 2026, Shoulder Innovations, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (64 of 100).

Will SI stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +40.3% from the last close, and Ticker Nerd's factor model ranks Shoulder Innovations, Inc. 27 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SI stock forecast for 2030?

No analyst covering Shoulder Innovations, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $28 over the next 12 months.

How has SI stock performed over the past year?

Shoulder Innovations, Inc. returned +23.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Shoulder Innovations, Inc. do?

Shoulder Innovations, Inc. is a commercial-stage medical technology company focused on shoulder arthroplasty solutions.

What is the latest news on SI?

The most recent item we track (PRNewsWire, 10 Sept 2026): "Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch". Shoulder Innovations received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity, and has initiated full commercial launch. This marks the second product introduction on the company's new line of technologies for metal-sensitive patients.

Company

About Shoulder Innovations, Inc.

Shoulder Innovations, Inc. is a commercial-stage medical technology company focused on shoulder arthroplasty solutions. Shoulder Innovations designs, develops, manufactures, and distributes implant systems and related surgical tools used in shoulder replacement procedures. Its product portfolio includes advanced total and reverse shoulder arthroplasty systems, tray components, planning software, and enabling instruments that support preoperative planning, implant placement, and procedural efficiency. The company’s InSet Glenoid technology is central to its platform, supporting fixation and stability in shoulder implants while addressing clinical challenges in shoulder reconstruction. Shoulder Innovations serves hospitals, ambulatory surgery centers, surgeons, and orthopedic care teams that rely on specialized devices for shoulder surgery. Headquartered in Grand Rapids, Michigan, Shoulder Innovations focuses exclusively on the shoulder surgical care market, making it a specialized participant in the broader orthopedic medical device industry.

CEO Mr. Robert Ball · 56 employees · United States · https://www.shoulderinnovations.com